 |
|
|
| |
The Prevalence and the Effect of HCV NS5A Resistance-Associated Variants in Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir ± RBV
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Christoph Sarrazin,1 Hadas Dvory-Sobol,2 Evguenia S. Svarovskaia,2 Brian Doehle,2 Ross Martin,2 Stefan Zeuzem,3 Eric Lawitz,4 Robert H. Hyland,2 Phil S. Pang,2 Xiao Ding,2 Steven Knox,2 Edward Gane,5 K. Rajender Reddy,6 Nezam Afdhal,7 Masashi Mizokami,8 Masao Omata,9 Michael D. Miller,2 Hongmei Mo,2 Marc Bourliere10
1Medizinische Klinik 1, Universitatsklinikum Frankfurt, Frankfurt am Main, Germany; 2Gilead Sciences, Inc., Foster City, California, USA; 3Goethe-Universitat, Frankfurt am Main, Germany; 4Texas Liver Institute, University of Texas Health Science Center at San Antonio, Texas, USA; 5New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand;
6University of Pennsylvania, Philadelphia, Pennsylvania, USA; 7Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 8Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Tokyo, Japan; 9Yamanashi Prefectural Hospital Organization, Yamanashi, Japan; 10Hopital Saint Joseph, Marseilles, France
|
| |
|
|
|
|
|
